| 产品描述: | MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2. |
| 靶点: |
ERK:5 nM (EC50); MEK1:3 nM (IC50) |
| 体外研究: |
MAP855 (3 mg/kg for i.v., 10 mg/kg for p.o.; single) has good oral bioavailability and medium clearance in rodents[1]. MAP855 (30 mg/kg; p.o., b.i.d, 14 days) achieves comparable efficacy to trametinib dosed at the mouse MTD without any body weight loss[1]. Pharmacokinetic Parameters of MAP855 in mouse, rat and dog[1]. |
| 体内研究: |
MAP855 (compound 30) has single-digit nM inhibition of pERK and proliferation in A375 cells (pERK EC50=5 nM). |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.77 ml |
8.85 ml |
17.7 ml |
| 5 mM |
0.354 ml |
1.77 ml |
3.54 ml |
| 10 mM |
0.177 ml |
0.885 ml |
1.77 ml |
| 50 mM |
0.035 ml |
0.177 ml |
0.354 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |